Background: The incidence of breast cancer has been on the rise in Malaysia. It is suggested that a subset of breast cancer cases were associated with germline mutation in breast cancer susceptibility (BRCA) genes. Most of the BRCA mutations reported in Malaysia were point mutations, small deletions and insertions. Here we report the first study of BRCA large genomic rearrangements (LGRs) in Malaysia. We aimed to detect the presence of LGRs in the BRCA genes of Malaysian patients with breast cancer.

Methods: Multiplex ligation-dependent probe amplification (MLPA) for BRCA LGRs was carried out on 100 patients (60 were high-risk breast cancer patients previously tested negative/positive for BRCA1 and BRCA2 mutations, and 40 were sporadic breast cancer patients), recruited from three major referral centres, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Hospital Kuala Lumpur (HKL) and Hospital Putrajaya (HPJ).

Results: Two novel BRCA1 rearrangements were detected in patients with sporadic breast cancer; both results were confirmed by quantitative PCR. No LGRs were found in patients with high-risk breast cancer. The two large genomic rearrangements detected were genomic amplifications of exon 3 and exon 10. No BRCA2 genomic rearrangement was found in both high-risk and sporadic breast cancer patients.

Conclusion: These results will be helpful to understand the mutation spectrum of BRCA1 and BRCA2 genes in Malaysian patients with breast cancer. Further studies involving larger samples are required to establish a genetic screening strategy for both high-risk and sporadic breast cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2010.04.010DOI Listing

Publication Analysis

Top Keywords

breast cancer
44
sporadic breast
16
large genomic
12
genomic rearrangements
12
breast
12
cancer patients
12
cancer
11
brca genes
8
genes malaysian
8
patients
8

Similar Publications

Background: Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecular subtypes, influence the therapeutic impact of NACT. Moreover, severe adverse events delay the treatment process and reduce the effectiveness of therapy.

View Article and Find Full Text PDF

Breast cancer patterns by age groups in Brazil: insights from population-based registries data.

BMC Cancer

January 2025

Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, 37 Andre Cavalcanti Street, 5th floor, Annex Building, 20231050, Rio de Janeiro, Brazil.

Background: Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.

Methods: BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC).

View Article and Find Full Text PDF

Automatic image generation and stage prediction of breast cancer immunobiological through a proposed IHC-GAN model.

BMC Med Imaging

January 2025

Electronics and Communications, Arab Academy for Science, Heliopolis, Cairo, 2033, Egypt.

Invasive breast cancer diagnosis and treatment planning require an accurate assessment of human epidermal growth factor receptor 2 (HER2) expression levels. While immunohistochemical techniques (IHC) are the gold standard for HER2 evaluation, their implementation can be resource-intensive and costly. To reduce these obstacles and expedite the procedure, we present an efficient deep-learning model that generates high-quality IHC-stained images directly from Hematoxylin and Eosin (H&E) stained images.

View Article and Find Full Text PDF

Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.

Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!